Solara’s Mangalore Site Clears US FDA Inspection with VAI Status
POWER & RENEWABLE ENERGY

Solara’s Mangalore Site Clears US FDA Inspection with VAI Status

Solara Active Pharma Sciences has announced the successful completion of the US Food and Drug Administration (US FDA) inspection at its multi-product Active Pharmaceutical Ingredient manufacturing facility in Mangalore, Karnataka. The inspection, conducted from 25 to 29 August 2025, concluded with the issuance of an Establishment Inspection Report (EIR) on 18 November 2025. The Agency classified the facility as “Voluntary Action Indicated” (VAI), confirming continued compliance with current Good Manufacturing Practices (cGMP) and formally closing the inspection.

According to the company, the US FDA issued two procedural Form 483 observations at the end of the inspection. Solara submitted a comprehensive response within the stipulated timeframe, following which the Agency acknowledged the adequacy of the corrective actions and closed the inspection. The company noted that the outcome reflects its commitment to regulatory excellence, robust quality systems and adherence to global compliance standards across all manufacturing sites.

The Mangalore facility is equipped with multiple independent production blocks and packaging units, enabling supply of a wide portfolio of APIs. It is also regularly inspected by leading global regulatory bodies, including EDQM, HPRA, TGA, WHO, PMDA and MFDS Korea. Solara stated that maintaining world-class quality and compliance remains central to its long-term growth strategy.

Solara Active Pharma Sciences has announced the successful completion of the US Food and Drug Administration (US FDA) inspection at its multi-product Active Pharmaceutical Ingredient manufacturing facility in Mangalore, Karnataka. The inspection, conducted from 25 to 29 August 2025, concluded with the issuance of an Establishment Inspection Report (EIR) on 18 November 2025. The Agency classified the facility as “Voluntary Action Indicated” (VAI), confirming continued compliance with current Good Manufacturing Practices (cGMP) and formally closing the inspection. According to the company, the US FDA issued two procedural Form 483 observations at the end of the inspection. Solara submitted a comprehensive response within the stipulated timeframe, following which the Agency acknowledged the adequacy of the corrective actions and closed the inspection. The company noted that the outcome reflects its commitment to regulatory excellence, robust quality systems and adherence to global compliance standards across all manufacturing sites. The Mangalore facility is equipped with multiple independent production blocks and packaging units, enabling supply of a wide portfolio of APIs. It is also regularly inspected by leading global regulatory bodies, including EDQM, HPRA, TGA, WHO, PMDA and MFDS Korea. Solara stated that maintaining world-class quality and compliance remains central to its long-term growth strategy.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code